These categories include SHL clotting factor concentrates; EHL clotting factor concentrates; 1 bispecific monoclonal antibody with regulatory authorization for the prevention of bleeding in people with hemophilia A and at least 2 others in clinical development; 1 rebalancing agent targeting tissue factor (TF) pathway inhibitor (TFPI) with regulatory authorization and a number of rebalancing agents in clinical development; and 3 gene therapy products, 1 for hemophilia A and 2 for hemophilia B with regulatory authorization and many more in different stages of development (Tables 1 and 2). This evidence concerns the gene TFPI and hemophilia A.